That is a vicious cycle that you describe there, lol.
That is a vicious cycle that you describe there, lol.
On the one hand you say BARDA could give us 700k. I would consider this a very BIG DEAL, and that relatively small amount of money wouldn't even be the most important part in this. For me announcement that BARDA now approved GNBT's application and from now on be listed on their website, would cause this company to finally be publicly recognized, and that let alone is worth more than the 700k of first funding that they may provide to GNBT.
The other thing, besides the extra publicity, that is much more important than 700k in cash, would be the clear statement that now BARDA believes in NGIO's technology and that they have a clear shot at getting a working vaccine developed and produced!!
But back to the vicious cycle, sorry I got distracted here, LOL. BARDA will likely not give GNBT/NGIO any approval or funding, unless they provide these positive lab results. So there you have it, even for the BARDA application, it is very important to finally have those test results available, and thus I fully agree with you on that very vital information that they should finally come out of the woods with.
3
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Crossing Continents for Women's Healing When Chelsey Goodan, an American expert in adolescent education, made her way to Hangzhou, China, it wasn't just another stop on her world tour. No, this was her first venture into China, rallying with Zhang Xinyuan, the brains behind Vimi Wellness. For those not in the know, Vimi's been pioneering women's intimate health and...
Continue Reading
UK Government Faces Job Data Reliability Crisis The UK government has recently identified a pressing challenge in acquiring dependable jobs data essential for effective economic policy-making. This issue has arisen due to flaws in the Labor Force Survey conducted by the Office for National Statistics (ONS), which is the main instrument used to gauge the UK job market. The...
Continue Reading
HII Announces Quarterly Cash Dividend HII (NYSE: HII) has made a significant declaration that is likely to resonate well with its shareholders. Recently, the company's Board of Directors confirmed a quarterly cash dividend of $1.35 per share to be distributed on June 13, 2025. This move underscores HII's ongoing commitment to its investors, as it rewards those holding...
Continue Reading
ZTE's Global Summit 2025: Shaping a Smarter Future in Milan Milan recently hosted a significant event as ZTE Corporation, a renowned leader in integrated information and communication technology solutions, gathered industry leaders from around the world. Under the theme "Expanding Intelligence, Creating Possibilities," the event focused on the crucial aspects of AI-driven...
Continue Reading
Dr. Stelios Papadopoulos Appointed to Ovid Therapeutics Board Ovid Therapeutics Inc. (NASDAQ: OVID), an innovative biopharmaceutical company, has made headlines with the announcement of Dr. Stelios Papadopoulos joining its Board of Directors. Known for his remarkable contributions to biotechnology, Dr. Papadopoulos brings with him a wealth of experience that promises to...
Continue Reading